)
India’s largest drugmaker by market share in the domestic pharmaceutical (pharma) market has stepped up its game in the US dermatology space with the acquisition of Concert Pharmaceuticals, Inc. (Concert), a Nasdaq-listed firm, for $576 million.
Concert is a biotechnology firm with an extensive patent portfolio. Its lead product candidate is deuruxolitinib, an oral drug for the treatment of alopecia areata, an autoimmune dermatological disease in late-stage development.
The deal size could expand up to $827 million (roughly Rs 6,800 crore) if the additional milestone-based payments are made.
Sun Pharmaceutical Industries (Sun Pharma) informed stock exchanges after market hours on Thursday that it
